BRPI0710944B8 - cultura biologicamente pura, e, composição e método para reduzir cólica infantil - Google Patents

cultura biologicamente pura, e, composição e método para reduzir cólica infantil

Info

Publication number
BRPI0710944B8
BRPI0710944B8 BRPI0710944A BRPI0710944A BRPI0710944B8 BR PI0710944 B8 BRPI0710944 B8 BR PI0710944B8 BR PI0710944 A BRPI0710944 A BR PI0710944A BR PI0710944 A BRPI0710944 A BR PI0710944A BR PI0710944 B8 BRPI0710944 B8 BR PI0710944B8
Authority
BR
Brazil
Prior art keywords
reduce
composition
pure culture
biologically pure
infantile colic
Prior art date
Application number
BRPI0710944A
Other languages
English (en)
Portuguese (pt)
Inventor
Möllstam Bo
Connolly Eamonn
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38790468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0710944(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogaia Ab filed Critical Biogaia Ab
Publication of BRPI0710944A2 publication Critical patent/BRPI0710944A2/pt
Publication of BRPI0710944B1 publication Critical patent/BRPI0710944B1/pt
Publication of BRPI0710944B8 publication Critical patent/BRPI0710944B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225Lactobacillus
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/853Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BRPI0710944A 2006-06-05 2007-05-30 cultura biologicamente pura, e, composição e método para reduzir cólica infantil BRPI0710944B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/446,628 2006-06-05
US11/446,628 US7374924B2 (en) 2006-06-05 2006-06-05 Use of selected lactic acid bacteria for reducing infantile colic
PCT/SE2007/050371 WO2007142596A1 (en) 2006-06-05 2007-05-30 Use of selected lactic acid bacteria for reducing infantile colic

Publications (3)

Publication Number Publication Date
BRPI0710944A2 BRPI0710944A2 (pt) 2017-04-18
BRPI0710944B1 BRPI0710944B1 (pt) 2020-12-29
BRPI0710944B8 true BRPI0710944B8 (pt) 2021-05-25

Family

ID=38790468

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0710944A BRPI0710944B8 (pt) 2006-06-05 2007-05-30 cultura biologicamente pura, e, composição e método para reduzir cólica infantil

Country Status (20)

Country Link
US (3) US7374924B2 (enExample)
EP (1) EP2040722B1 (enExample)
JP (3) JP4520531B2 (enExample)
KR (2) KR101308865B1 (enExample)
CN (2) CN102488717B (enExample)
AU (2) AU2007200434B2 (enExample)
BR (1) BRPI0710944B8 (enExample)
CA (1) CA2650546C (enExample)
DK (1) DK2040722T3 (enExample)
GE (1) GEP20125480B (enExample)
HU (1) HUE026416T2 (enExample)
IL (1) IL194779A0 (enExample)
MX (1) MX2008014869A (enExample)
MY (1) MY162708A (enExample)
NZ (2) NZ596788A (enExample)
RU (1) RU2435844C2 (enExample)
SI (1) SI2040722T1 (enExample)
UA (1) UA93911C2 (enExample)
WO (1) WO2007142596A1 (enExample)
ZA (1) ZA200809531B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
EP2265135B1 (en) * 2008-03-14 2017-12-20 Nestec S.A. Synbiotic mixture
AU2014221272B2 (en) * 2008-11-03 2016-01-21 Société des Produits Nestlé S.A. A nutritional composition comprising probiotics and improving sleep patterns
RU2517616C2 (ru) * 2008-11-03 2014-05-27 Нестек С.А. Питательная композиция, включающая пробиотики и улучшающая характер сна
US20110104327A1 (en) * 2009-04-23 2011-05-05 Bacterfield International S.A. Probiotic pet food
SG177541A1 (en) 2009-07-31 2012-02-28 Nestec Sa Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients
NL2004101C2 (en) * 2010-01-15 2011-07-18 Friesland Brands Bv Ruminant il-10 and use in modulating immune response.
IT1401460B1 (it) * 2010-06-11 2013-07-26 Probiotical Spa "ceppi di batteri probiotici produttori di vitamina b12"
KR101706100B1 (ko) * 2011-12-15 2017-02-15 삼성전자주식회사 성형한계선도 획득용 시험장치
EP2609813A1 (en) * 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system
UA118339C2 (uk) * 2012-09-03 2019-01-10 Біогайа Аб Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
WO2015018883A2 (en) * 2013-08-09 2015-02-12 Ab-Biotics, S.A. Probiotic for infantile excessive crying
AU2015209763B2 (en) 2014-01-23 2020-12-24 Biogaia Ab Selection of agents modulating gastrointestinal pain
CN106794207A (zh) * 2014-10-29 2017-05-31 雀巢产品技术援助有限公司 使用罗伊氏乳杆菌在生命早期恢复微生物群生态失调
EP3294308A4 (en) 2015-05-14 2019-03-06 University of Puerto Rico PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN
JP6529835B2 (ja) * 2015-06-23 2019-06-12 株式会社フィス 樹状細胞活性化剤
CN105219683B (zh) * 2015-11-04 2018-03-13 广东省农业科学院动物科学研究所 一株具有益生特征的罗伊氏乳杆菌菌株及其应用
WO2017117142A1 (en) 2015-12-28 2017-07-06 New York University Device and method of restoring microbiota of newborns
CN106497840B (zh) * 2016-11-07 2019-06-21 江南大学 一种定向分离免疫调节性肠道乳杆菌的方法
CN117487686A (zh) * 2018-07-24 2024-02-02 生命大地女神有限公司 选择和使用褪黑素支持细菌以减少婴儿绞痛
MX2020014222A (es) * 2018-07-24 2021-03-09 Biogaia Ab Metodos terapeuticos que utilizan cepas bacterianas las cuales son capaces de aumentar los niveles de adenosina.
SG11202110355RA (en) * 2019-04-17 2021-11-29 Biogaia Ab Therapeutic microvesicles of probiotic bacteria
US20240165171A1 (en) * 2021-03-26 2024-05-23 Seoul National University R&Db Foundation Composition for enhancing physiological efficacy of lactic acid bacteria
CN117925484B (zh) * 2024-03-19 2024-07-09 山东中科嘉亿生物工程有限公司 一株改善睡眠呼吸暂停的罗伊氏粘液乳杆菌jylb-101及其产品和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518696A (en) 1983-01-11 1985-05-21 Chr. Hansen's Laboratory, Inc. Stabilized liquid bacterial suspension for oral administration to animals
US5413960A (en) 1987-05-01 1995-05-09 Biogaia Ab Antibiotic reuterin
US5458875A (en) 1990-06-15 1995-10-17 Biogaia Ab In ovo method for delivering Lactobacillus reuteri to the gastrointestinal tract of poultry
US5534253A (en) 1995-06-07 1996-07-09 Biogaia Ab Method of treating enteropathogenic bacterial infections in poultry
AU718040B2 (en) 1995-12-21 2000-04-06 Abbott Laboratories Use of lactobacillus reuteri to inhibit cryptosporidiosis in mammals
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US5800813A (en) 1996-11-12 1998-09-01 Biogaia Biologics Ab Treatment of cryptosporidium infections
KR19990024297A (ko) 1997-08-07 1999-04-06 오종석 인체 구강내 치태형성을 억제하는 신규한 유산균
US6100388A (en) 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
EP1034788A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactic acid bacteria strains capable of preventing diarrhea
EP1344458A1 (en) * 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
US7105336B2 (en) 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
EP1567018B1 (en) * 2002-10-18 2009-07-01 Biogaia Ab Method of improving immune function in mammals using lactobacillus reuteri strains
US20040208863A1 (en) 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
US20040185032A1 (en) 2003-03-18 2004-09-23 David Burrell Compositions and methods for treating colic
EP1638414B1 (en) * 2003-06-23 2009-06-17 Nestec S.A. Infant or follow-on formula
US7955834B2 (en) * 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
US20060251634A1 (en) * 2005-05-06 2006-11-09 Ho-Jin Kang Method of improving immune function in mammals using lactobacillus strains with certain lipids
US8603460B2 (en) * 2006-06-05 2013-12-10 Brogaia AB Method of making a Lactobacillus reuteri with increased acid tolerance
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic

Also Published As

Publication number Publication date
BRPI0710944A2 (pt) 2017-04-18
HUE026416T2 (en) 2016-07-28
SI2040722T1 (sl) 2016-02-29
AU2007200434A1 (en) 2007-12-20
EP2040722A4 (en) 2010-06-02
JP4520531B2 (ja) 2010-08-04
EP2040722B1 (en) 2015-11-11
RU2008147883A (ru) 2010-07-20
DK2040722T3 (en) 2016-02-01
NZ596788A (en) 2013-03-28
US7374924B2 (en) 2008-05-20
RU2435844C2 (ru) 2011-12-10
JP2010202654A (ja) 2010-09-16
UA93911C2 (ru) 2011-03-25
ZA200809531B (en) 2010-03-31
CN101374533A (zh) 2009-02-25
EP2040722A1 (en) 2009-04-01
JP2009539371A (ja) 2009-11-19
JP2013173749A (ja) 2013-09-05
CN102488717B (zh) 2018-03-27
JP5865283B2 (ja) 2016-02-17
US9340840B2 (en) 2016-05-17
HK1125840A1 (en) 2009-08-21
KR101308865B1 (ko) 2013-09-17
CA2650546C (en) 2011-08-02
CN101374533B (zh) 2012-02-01
MX2008014869A (es) 2008-12-05
WO2007142596A1 (en) 2007-12-13
KR20090015903A (ko) 2009-02-12
NZ572359A (en) 2011-12-22
GEP20125480B (en) 2012-04-25
AU2010202976A1 (en) 2010-08-05
CN102488717A (zh) 2012-06-13
BRPI0710944B1 (pt) 2020-12-29
KR101030661B1 (ko) 2011-04-20
AU2010202976B2 (en) 2012-12-20
CA2650546A1 (en) 2007-12-13
AU2007200434B2 (en) 2010-09-02
MY162708A (en) 2017-07-14
KR20100080565A (ko) 2010-07-08
US20080131414A1 (en) 2008-06-05
IL194779A0 (en) 2009-08-03
US20120121564A1 (en) 2012-05-17
US20070280913A1 (en) 2007-12-06
US9057112B2 (en) 2015-06-16

Similar Documents

Publication Publication Date Title
BRPI0710944B8 (pt) cultura biologicamente pura, e, composição e método para reduzir cólica infantil
Clarke Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via nod-like receptor ligands
MY172363A (en) Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof
EP2490751A4 (en) METHOD AND SYSTEMS FOR PROVIDING ERYTHROCYTE PRODUCTS WITH REDUCED PLASMA
SG196782A1 (en) Compositions and methods for the increased production of isoprene and other products with 6 - phosphogluconolactonase (pgl)
UA101316C2 (ru) Применение отобранных молочнокислых бактерий для профилактики и лечения атеросклероза
BRPI0412978A (pt) cultura biologicamente pura de grupo bacteriano, co-cultura bacteriana, composição terapêutica, aditivo ou suplemento alimentar, gênero alimentìcio, método para tratar ou prevenir desordem e artigo de manufatura
MX2009012140A (es) Procesamiento de polisacaridos naturales mediante microorganismos no patogenos seleccionados y metodos de fabricacion y uso de los mismos.
EP4560007A3 (en) Compositions for metabolic health
UA107711C2 (en) Use of lactobacilli inhibiting gas producing coliform bacteria isolated from infants affected by colic
NZ598751A (en) Anti-obesity agent, anti-obesity food or beverage, glucose tolerance-ameliorating agent, and food or beverage for amelioration of glucose tolerance (bifidobacterium breve mcc1274 (ferm bpp-11175))
CA2710814C (en) Bacterial ghost (bg) production process using betapropiolactone (blp) for final inactivation
GB0421448D0 (en) A method for producing metabolically active micro organisms
Dierksen et al. The effect of ingestion of milk supplemented with salivaricin A-producing Streptococcus salivarius on the bacteriocin-like inhibitory activity of streptococcal populations on the tongue
RU2010147885A (ru) Применение пробиотических бактерий для лечения гипергомоцистеинемии
MX2012007970A (es) Proceso para la preparacion de una biomasa que comprende plantaricina y usos de la misma en el campo medico.
WO2023092141A3 (en) Compositions for metabolic health
IL194353A0 (en) Lysobactin amides
RU2007146645A (ru) Препарат бактериальный для производства ферментированных мясных изделий и биотрансформации мясного сырья
EP2194125A3 (en) New antibiotic-sensitive lactic acid bacteria strains
RU2009105957A (ru) Способ приготовления силоса
EP2548945A3 (en) Lactic acid bacterium with increased acid tolerance
GB2465307A (en) Modified chondroitinase polypeptides
WO2011017565A3 (en) Methods and compositions for controlling contamination growth in cell cultures
Fadahunsi et al. HEAT STABILITY AND OPTIMIZATION OF INVITRO ANTIMICROBIAL ACTIVITY OF METABOLITES PRODUCED BY RHIZOPUS OLIGOSPORUS NRRL 2710 AGAINST SOME PATHOGENIC BACTERIA.

Legal Events

Date Code Title Description
B15V Prolongation of time limit allowed

Free format text: REQUERENTE DA DEVOLUCAO DE PRAZO: A DEPOSITANTE - BIOGAIA AB. DESPACHO: CONCEDIDA A DEVOLUCAO DE PRAZO PARA ENTRADA NA FASE NACIONAL DO PEDIDO PCT/SE2007/050371, DE 30/05/2007.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: INTERESSADA: A DEPOSITANTE - BIOGAIA AB. DESPACHO: ARQUIVADA A PETICAO NO 200801252659 (RJ), DE 11/12/2008 POR AUSENCIA DO INSTRUMENTO DE PROCURACAO CONFORME ART. 216 2O DA LPI.

B12F Other appeals [chapter 12.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/05/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22B Petition not considered [chapter 22.2 patent gazette]

Free format text: PI0710944-0: NAO CONHECIDA A PETICAO NO 870210061832, DE 07/07/2021, EM VIRTUDE DO DISPOSTO NO ART. 219 , INCISO II DA LPI

B12F Other appeals [chapter 12.6 patent gazette]

Free format text: RECURSO: 870220037926 - 2/05/2022